Key statistics
On Friday, SAB Biotherapeutics Inc (SABS:NAQ) closed at 3.13, 44.91% above the 52 week low of 2.16 set on Aug 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.22 |
---|---|
High | 3.22 |
Low | 3.00 |
Bid | 3.00 |
Offer | 3.13 |
Previous close | 3.07 |
Average volume | 75.61k |
---|---|
Shares outstanding | 9.23m |
Free float | 7.46m |
P/E (TTM) | -- |
Market cap | 28.33m USD |
EPS (TTM) | -5.84 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
- SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
- SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
- SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
- SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
- SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
- SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
- SAB BIO Appoints Lucy To as Chief Financial Officer
- SAb Biotherapeutics Rebrands as SAB BIO
- SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
More ▼